LACTOLOGY FOUNDATION

Neomycin combinations (ATC A07AA51) are oral intestinal antibiotic preparations in which neomycin is the main active component, combined with other antimicrobials to target gastrointestinal infections while acting largely within the gut lumen. Because oral neomycin is poorly absorbed and systemic exposure is low, these combinations generally pose a low theoretical risk to breastfed infants, although specific lactation data for individual combination products are limited.atcddd.fhi+3

Pharmacological class and composition

A07AA51 comprises combinations where neomycin has classification priority and is formulated together with other intestinal antibiotics or antimicrobials for local action in the gastrointestinal tract. Typical products include fixed‑dose combinations used for intestinal decontamination, infectious diarrhea, or prophylaxis in gastrointestinal surgery, with neomycin providing broad aminoglycoside coverage against aerobic gram‑negative flora.atcddd.fhi+3

Mechanism of action

Neomycin is an aminoglycoside that binds to the 30S ribosomal subunit of susceptible bacteria, disrupting protein synthesis and exerting a bactericidal effect. In combinations, neomycin’s activity is complemented by partner agents (for example, other antibiotics acting on different targets), producing additive or synergistic suppression of intestinal bacteria associated with infection or hepatic encephalopathy.atcddd.fhi+3

Pharmacokinetics relevant to lactation

Orally administered neomycin is very poorly absorbed from the gastrointestinal tract, so systemic concentrations remain low and most of the administered dose is recovered unchanged in feces. This pharmacokinetic profile indicates that maternal plasma levels after oral dosing are minimal, which in turn suggests that excretion into breast milk, if any, is likely to be very small.drugs+2

Maternal toxicity and adverse effects

Despite low absorption, chronic or high‑dose oral neomycin can cause significant toxicity (ototoxicity, nephrotoxicity, neuromuscular blockade) because any absorbed fraction behaves like other aminoglycosides. More commonly, oral neomycin combinations cause gastrointestinal adverse effects such as nausea, vomiting, diarrhea, or malabsorption, and may alter intestinal flora, which is particularly relevant in patients with pre‑existing gut disease or hepatic impairment.pmc.ncbi.nlm.nih+3

Excretion into breast milk

No direct measurements of neomycin concentrations in human milk have been published, but experience with aminoglycosides indicates poor excretion into breast milk. Expert lactation resources state that oral neomycin, because of minimal absorption, is unlikely to be present in breast milk in clinically significant amounts and is considered very low risk for the breastfed infant.drugs+1

Reported effects in breastfed infants

There are no documented cases of systemic toxicity in breastfed infants attributable to maternal use of oral neomycin or its intestinal combinations. Theoretical concerns focus on possible disturbance of the infant gut microbiota and rare antibiotic‑associated colitis, similar to other oral antibiotics, but these effects have not been specifically linked to neomycin combinations in the lactation literature.pmc.ncbi.nlm.nih+3

Impact on lactation and breast milk

There is no evidence that neomycin or its combinations reduce milk supply or directly affect the endocrine regulation of lactation. General guidance on medicine use in breastfeeding notes that most drugs, especially those with low oral availability and short systemic exposure, can be used safely when clinically indicated, provided doses and duration are minimized.europeanjournalofmidwifery+2

Clinical use in breastfeeding

In breastfeeding women, oral neomycin combinations may be used for indicated gastrointestinal infections or pre‑operative bowel decontamination after weighing maternal benefit against theoretical infant risk. Given the low expected milk transfer and poor infant oral absorption, many authorities consider aminoglycosides such as neomycin usually compatible with breastfeeding, although caution is advised for prolonged courses or in mothers of premature or medically fragile infants.atcddd.fhi+4

Infant monitoring recommendations

When a lactating mother receives an A07AA51 neomycin combination, routine infant monitoring focuses on clinical signs rather than laboratory testing. Caregivers should watch for gastrointestinal disturbances (diarrhea, constipation, blood in stool), oral or diaper candidiasis, or unusual irritability, and seek medical evaluation if such symptoms occur, as they may indicate antibiotic‑associated changes in gut flora.pmc.ncbi.nlm.nih+2

Risk–benefit assessment

If neomycin combinations are clearly indicated—for example, in hepatic encephalopathy regimens or high‑risk bowel surgery prophylaxis—the maternal and overall clinical benefits often outweigh the small, theoretical risks to the breastfed infant. When alternative intestinal antibiotics with more robust lactation data are suitable, these may be preferred for short, non‑critical indications, particularly in neonates, while still recognizing the strong benefits of continuing breastfeeding.medsafe+4

Key counselling points

Healthcare professionals should explain that neomycin in A07AA51 combinations acts mainly in the intestine, is poorly absorbed, and therefore is unlikely to appear in breast milk or cause systemic toxicity in the infant, although direct milk data are lacking. Mothers should be encouraged to continue breastfeeding when treatment is necessary, using the lowest effective dose and shortest course, and to monitor their infants for gastrointestinal or candidal symptoms during therapy.drugs+3